Researchers found a 44% relative drop over five years, though an outside expert told Newsweek that equals about 3 to 5 points. They also flag a lithium toxicity risk early on.
Recap by typeshit. Full story at Newsweek.
Avi Roy points out that the largest test so far found no memory benefit from the drug in Ozempic, despite hopes raised by health record studies.
Balwinder Singh and Raman Baweja link GLP-1 use to less kidney replacement therapy in bipolar patients with CKD, and flag lithium toxicity cases.
Yale Medicine says 5% to 10% of people on GLP-1 weight loss drugs see little result, and points to diet as one factor that can blunt the effect.
24:26
A doctor's explainer sorting peptides into eight broad categories. An evergreen overview for anyone still learning the basics.
Benjamin Bikman notes participants lost 12 to 22% of body weight on Lilly's triple agonist, and argues the drug works through weight loss rather than the airway itself.
Demand for protein is climbing alongside GLP-1 use, and Reuters reports shoppers are looking harder at what those products actually deliver.
Loading…